NS5Aのアロステリック調節によるダクラタスウィル耐性C型肝炎の再敏感化

Jin-Hua Sun¹, Donald R O'Boyle¹, Robert A Fridell¹

¹Department of Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, USA.

Nature

|November 5, 2015

まとめ

C型肝炎ウイルス (HCV) の直接作用の抗ウイルス薬であるダクラタスビル (DCV) は,NS5A阻害剤の同類剤と併用すると,効能が強化される. この組み合わせは耐性を克服し,慢性的なHCV感染の治療効果を向上させます.

科学分野:

ウイルス学
ヘパトロジー
薬理学について

背景:

C型肝炎ウイルス (HCV) は,全世界で1,700万人以上の人々に感染しています.
直接作用の抗ウイルス薬 (DAA) の併用療法では,HCVの根絶の可能性があります.
HCVの非構造タンパク質5A (NS5A) は,ウイルスの複製に不可欠であり,ダクラタスビル (DCV) のような強力な阻害剤の標的である.

研究の目的:

ダクラタスビル (DCV) の特異的な効能を理解するために
DCV と NS5A 阻害剤アナログ (Syn-395) を併用したシナジスティック効果を調査する.
HCVの併用療法と耐性に対する影響を調査する.

主な方法:

HCV NS5A変種に対するDCVとSyn-395のインビトロ評価
耐性NS5A変種に対する併用療法の有効性の評価
HCVに感染したキメアマウスモデルを用いた in vivo 検証

主要な成果:

DCVとSyn-395は,個々のNS5A耐性変種に対して限られた活性を示した.
DCVとSyn-395を併用すると,効能が1,000倍以上増加し,ピコモラ (pM) 範囲に活性が回復しました.
NS5Aタンパク質の間のコミュニケーションを示唆するシナガティック効果が in vivoで確認されました.

結論:

NS5A阻害剤の組み合わせは抵抗を克服し,抗HCV活性を大幅に高めることができます.
NS5Aの形状の変化を含むメカニズムを示唆しています.
このアプローチは,HCV併用治療の改善された選択肢を提供し,NS5A機能の理解を深める.

さらに関連する動画

13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

関連する概念動画

01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

01:20

Desensitization and Tachyphylaxis

3.4K

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

3.4K

01:08

Allosteric Regulation

64.6K

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...

64.6K

01:12

GPCR Desensitization

8.7K

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...